Like CML, relapsed Ph positive ALL patients exhibit similar mutations in BCR-ABL that impart TKI resistance, requiring a move to second and third generation BCR-ABL inhibitors. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.